Namwiwat Medical

BK:NAM Thailand Medical Devices
Market Cap
$72.27 Million
฿2.51 Billion THB
Market Cap Rank
#29087 Global
#554 in Thailand
Share Price
฿3.58
Change (1 day)
-3.24%
52-Week Range
฿3.46 - ฿4.48
All Time High
฿7.17
About

Namwiwat Medical Corporation Public Company Limited manufactures and distributes medical equipment in Thailand. The company provides medical supplies, disinfection services, medical equipment maintenance services, infectious waste services, and other medical services. It also offers equipment rental and contractual construction services. The company was formerly known as Namwiwat Engineering (199… Read more

Namwiwat Medical (NAM) - Net Assets

Latest net assets as of June 2024: ฿1.95 Billion THB

Based on the latest financial reports, Namwiwat Medical (NAM) has net assets worth ฿1.95 Billion THB as of June 2024.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (฿2.34 Billion) and total liabilities (฿389.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ฿1.95 Billion
% of Total Assets 83.37%
Annual Growth Rate 96.24%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 53.83

Namwiwat Medical - Net Assets Trend (2021–2024)

This chart illustrates how Namwiwat Medical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Namwiwat Medical (2021–2024)

The table below shows the annual net assets of Namwiwat Medical from 2021 to 2024.

Year Net Assets Change
2024-06-30 ฿1.96 Billion +62.17%
2023-06-30 ฿1.21 Billion +178.79%
2022-06-30 ฿434.12 Million +67.22%
2021-06-30 ฿259.61 Million --

Equity Component Analysis

This analysis shows how different components contribute to Namwiwat Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 52.7% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2024)

Component Amount Percentage
Retained Earnings ฿118.03 Million 6.01%
Other Components ฿1.84 Billion 93.99%
Total Equity ฿1.96 Billion 100.00%

Namwiwat Medical Competitors by Market Cap

The table below lists competitors of Namwiwat Medical ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Namwiwat Medical's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,210,302,137 to 1,962,751,621, a change of 752,449,483 (62.2%).
  • Net income of 200,749,511 contributed positively to equity growth.
  • Dividend payments of 232,050,000 reduced retained earnings.
  • New share issuances of 784,075,330 increased equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ฿200.75 Million +10.23%
Dividends Paid ฿232.05 Million -11.82%
Share Issuances ฿784.08 Million +39.95%
Other Changes ฿-325.36K -0.02%
Total Change ฿- 62.17%

Book Value vs Market Value Analysis

This analysis compares Namwiwat Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.28x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 9.65x to 1.28x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2021-06-30 ฿0.37 ฿3.58 x
2022-06-30 ฿0.62 ฿3.58 x
2023-06-30 ฿1.73 ฿3.58 x
2024-06-30 ฿2.80 ฿3.58 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Namwiwat Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 10.23%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 18.24%
  • • Asset Turnover: 0.47x
  • • Equity Multiplier: 1.20x
  • Recent ROE (10.23%) is below the historical average (21.66%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2022 40.23% 17.60% 0.94x 2.43x ฿131.24 Million
2023 14.52% 15.98% 0.65x 1.40x ฿54.68 Million
2024 10.23% 18.24% 0.47x 1.20x ฿4.47 Million

Industry Comparison

This section compares Namwiwat Medical's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $153,312,034
  • Average return on equity (ROE) among peers: 62.17%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Namwiwat Medical (NAM) ฿1.95 Billion 40.23% 0.20x $8.82 Million
Business Alignment Public Company Limited (BIZ) $153.31 Million 62.17% 2.02x $24.47 Million